Compare Honest Company Inc (HNST) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Novartis AG — how do they compare? Honest Company Inc trades at $5.19 (market cap $558.95M), while Novartis AG trades at $152.65 (market cap $295.37B). The key difference: Novartis AG is far larger — about 528.4× Honest Company Inc's market cap, and Novartis AG pays a 3.07% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals.
| HNST | NVS | |
|---|---|---|
Market Cap | $558.95M | $295.37B |
Sector | Consumer Staples | Health |
52-Week High | $5.46 | $168.62 |
52-Week Low | $2.10 | $119.31 |
Enterprise Value | $462.56M | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.23, down 4.21% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows mixed fundamentals with Q2 2026 EPS beating estimates at $0.04 versus $0.00926 expected, though revenue declined to $342M in 2026 with a net loss of $12M. Operating cash flow improved to $57M in 2026, and strategic exits are showing progress according to recent company updates.
The outlook remains cautious due to persistent net losses and margin pressure, offset by improving cash flow and recent earnings beats. Key risks include sustained profitability challenges and competitive pressures in personal care markets, while analyst sentiment is mixed with 30% buy ratings amid ongoing turnaround efforts.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
